238 related articles for article (PubMed ID: 17659636)
21. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
Dewey RB; Reimold SC; O'Suilleabhain PE
Arch Neurol; 2007 Mar; 64(3):377-80. PubMed ID: 17353380
[TBL] [Abstract][Full Text] [Related]
22. [Valvular heart disease associated with the treatment of Parkinson disease].
Rasmussen VG; Dupont E; Østergaard K; Egeblad H
Ugeskr Laeger; 2006 Jun; 168(26-32):2542-4. PubMed ID: 16824407
[TBL] [Abstract][Full Text] [Related]
23. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
[TBL] [Abstract][Full Text] [Related]
24. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
Grosset K; Needleman F; Macphee G; Grosset D
Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984
[TBL] [Abstract][Full Text] [Related]
25. The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008.
Ooba N; Yamaguchi T; Kubota K
Drug Saf; 2011 Apr; 34(4):329-38. PubMed ID: 21417505
[TBL] [Abstract][Full Text] [Related]
26. Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.
Chaudhuri KR; Dhawan V; Basu S; Jackson G; Odin P
Mov Disord; 2004 Dec; 19(12):1522-3. PubMed ID: 15515009
[No Abstract] [Full Text] [Related]
27. [Cardiac valvulopathy and dopamine agonist].
Grandas F
Neurologia; 2007 Dec; 22(10):870-81. PubMed ID: 17671852
[TBL] [Abstract][Full Text] [Related]
28. [Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use].
van Strater AC; Bax JJ; van Hilten JJ; Jukema JW
Ned Tijdschr Geneeskd; 2005 Apr; 149(16):891-4. PubMed ID: 15868996
[TBL] [Abstract][Full Text] [Related]
29. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study.
Peralta C; Wolf E; Alber H; Seppi K; Müller S; Bösch S; Wenning GK; Pachinger O; Poewe W
Mov Disord; 2006 Aug; 21(8):1109-13. PubMed ID: 16622856
[TBL] [Abstract][Full Text] [Related]
30. Heart valve abnormalities in Parkinson's disease treated with dopamine agonists.
Bares M; Rektorová I; Krajcovicová L; Rektor I
J Neurol; 2008 Oct; 255(10):1596; author reply 1597. PubMed ID: 18758889
[No Abstract] [Full Text] [Related]
31. [Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].
Steffensen C; Mægbæk ML; Laurberg P; Andersen M; Kistorp C; Nørrelund H; Dal J; Jørgensen JO
Ugeskr Laeger; 2014 Jan; 176(1):58-60. PubMed ID: 24629610
[TBL] [Abstract][Full Text] [Related]
32. Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease.
Montastruc F; Moulis F; Araujo M; Chebane L; Rascol O; Montastruc JL
Eur J Clin Pharmacol; 2017 Jan; 73(1):99-103. PubMed ID: 27796464
[TBL] [Abstract][Full Text] [Related]
33. DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S53-67. PubMed ID: 12211141
[No Abstract] [Full Text] [Related]
34. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
Kvernmo T; Härtter S; Burger E
Clin Ther; 2006 Aug; 28(8):1065-1078. PubMed ID: 16982285
[TBL] [Abstract][Full Text] [Related]
35. [Pergolide use and heart valve fibrosis. Yearly control in patients with Parkinson disease who use pergolide].
van Laar T; Berendse H; Bloem BR; Boon AJ; van Hilten JJ; Hovestadt A; de Koning-Tijssen MA; Nijssen PC; Weber WE
Ned Tijdschr Geneeskd; 2009 Jan; 153(3):87-90. PubMed ID: 19235345
[No Abstract] [Full Text] [Related]
36. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide.
Jiménez-Jiménez FJ; López-Alvarez J; Sánchez-Chapado M; Montero E; Miquel J; Sierra A; Gutiérrez F
Clin Neuropharmacol; 1995 Jun; 18(3):277-9. PubMed ID: 8635187
[TBL] [Abstract][Full Text] [Related]
37. DA agonists -- ergot derivatives: cabergoline: management of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S68-71. PubMed ID: 12211142
[No Abstract] [Full Text] [Related]
38. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists.
Drake WM; Stiles CE; Howlett TA; Toogood AA; Bevan JS; Steeds RP;
J Clin Endocrinol Metab; 2014 Jan; 99(1):90-6. PubMed ID: 24187407
[TBL] [Abstract][Full Text] [Related]
39. Drug-induced valvular heart disease.
Cosyns B; Droogmans S; Rosenhek R; Lancellotti P
Heart; 2013 Jan; 99(1):7-12. PubMed ID: 22875739
[TBL] [Abstract][Full Text] [Related]
40. High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
Oeda T; Masaki M; Yamamoto K; Mizuta E; Kitagawa N; Isono T; Taniguchi S; Doi K; Yaku H; Yutani C; Kawamura T; Kuno S; Sawada H
J Neural Transm (Vienna); 2009 Feb; 116(2):171-8. PubMed ID: 19082526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
